TMPRSS2 and COVID-19: Therapies for COVID-19 include use of human recombinant soluble ACE2 to act as decoy receptors for binding and neutralizing SARS-CoV-2 [99,100] and inhibition TMPRSS2 activity to prevent spike protein priming [101,102].